Impact of maintenance immunosuppressive regimens - Balance between graft protective suppression of immune functions and a near physiological immune response

Transplant International

Volumn 24, Issue 6, 2011, Pages 596-609

  Weimer, Rolf ^a   Deisz, Sabine ^a   Dietrich, Hartmut ^a   Renner, Fabrice ^a   Bödeker, Rolf Hasso ^a   Daniel, Volker ^b   Kamali Ernst, Shirin ^c   Ernst, Wolfgang ^c   Padberg, Winfried ^a   Opelz, Gerhard ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Dialysis Centers   (Germany)

Author keywords

B cell; cytokines; immunosuppression; kidney transplantation; T helper cells

Indexed keywords

AZATHIOPRINE; CD30 ANTIGEN; CYCLOSPORIN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6 RECEPTOR; MITOGENIC AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEOPTERIN; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; B LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SECRETORY CELL; STAPHYLOCOCCUS; TH1 CELL; TH2 CELL; TREATMENT OUTCOME;

ADULT; AZATHIOPRINE; CD4-POSITIVE T-LYMPHOCYTES; CYCLOSPORINE; CYTOKINES; FEMALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; INTERLEUKIN-2; INTERLEUKIN-4; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME;

EID: 79955558933     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01241.x     Document Type: Article

References (42)

1. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
2. Bodziak KA, Hricik DE,. New-onset diabetes mellitus after solid organ transplantation. Transplant Int 2009; 22: 519.
3. Dharnidharka VR, Cherikh WS, Abbott KC,. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009; 87: 1019.
4. Fishman JA,. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601.
5. Opelz G, Döhler B,. Lymphomas after solid organ transplantation: a Collaborative Transplant Study report. Am J Transplant 2003; 4: 222.
6. Robson R, Cecka JM, Opelz G, Budde M, Sacks S,. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5: 2954.
7. Opelz G, Naujokat C, Daniel V, Terness P, Döhler B,. Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation 2006; 81: 1227.
8. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM,. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a metaanalysis. Lancet 2007; 370: 59.
9. Weimer R, Zipperle S, Daniel V, Carl S, Staehler G, Opelz G,. Pretransplant CD4 helper function and IL-10 response predict risk of acute kidney graft rejection. Transplantation 1996; 62: 1606.
10. Weimer R, Zipperle S, Daniel V, Carl S, Staehler G, Opelz G,. Superior 3-year kidney graft function in patients with impaired pretransplant Th2 responses. Transplant Int 1998; 11 (Suppl. 1): 350.
11. Weimer R, Streller S, Staak A, et al. Effects of three immunosuppressive regimens on CD4 helper function, B cell/monocyte and cytokine responses in renal transplant recipients: 4 month follow-up of a prospective randomized study. Transplant Proc 2002; 34: 2377.
12. Weimer R, Pomer S, Staehler G, Opelz G,. Increased T suppressor activity in renal transplant recipients with long-term stable graft function. Clin Transplant 1990; 4: 280.
13. Pellegrini P, Berghella AM, Contasta I, Adorno D,. CD30 antigen: not a physiological marker of TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol 2003; 12: 49.
14. Süsal C, Pelzl S, Döhler B, Opelz G,. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002; 13: 1650.
15. Süsal C, Pelzl S, Opelz G,. Strong HLA matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation 2003; 76: 1231.
16. Weimer R, Daniel V, Pomer S, Opelz G,. B lymphocyte response as an indicator of acute renal transplant rejection. II. Pretransplant and posttransplant B cell responses of mitogen and donor cell-stimulated cultures. Transplantation 1989; 48: 572.
17. Weimer R, Daniel V, Pomer S, Opelz G,. Pretransplant B cell response in vitro predicts risk of early kidney graft rejection. Transplant Proc 1990; 22: 1883.
18. Weimer R, Zipperle S, Daniel V, Pomer S, Staehler G, Opelz G,. IL-6 independent monocyte/B cell defect in renal transplant recipients with long-term stable graft function. Transplantation 1994; 57: 54.
19. Terasaki PI, Cai J,. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation 2008; 86: 377.
20. Eng HS, Bennett G, Bardy P, Coghlan P, Russ GR, Coates PT,. Clinical significance of anti-HLA antibodies detected by Luminex: enhancing the interpretation of CDC-BXM and important posttransplantation monitoring tools. Hum Immunol 2009; 70: 595.
21. Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9: 1063.
22. Lachmann N, Terasaki PI, Budde K, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87: 1505.
23. Lee PC, Zhu L, Terasaki PI, Everly MJ,. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009; 88: 568.
24. Weimer R, Mytilineos J, Feustel A, et al. Mycophenolate mofetil-based immunosuppression and cytokine genotypes: effects on monokine secretion and antigen presentation in long-term renal transplant recipients. Transplantation 2003; 75: 2090.
25. Palomar R, Ruiz JC, Mayorga M, et al. The macrophage infiltration index and matrix metalloproteinase-II expression as a predictor of chronic allograft rejection. Transplant Proc 2004; 36: 2662.
26. Yehia M, Matheson PJ, Merrilees MJ, Beaumont BW, Pilmore HL,. Predictors of chronic allograft nephropathy from protocol biopsies using histological and immunohistochemical techniques. Nephrology 2006; 11: 261.
27. Weimer R, Süsal C, Yildiz S, et al. Posttransplant sCD30 and neopterin as predictors of chronic allograft nephropathy-impact of different immunosuppressive regimens. Am J Transplant 2006; 6: 1865.
28. Weimer R, Melk A, Daniel V, Friemann S, Padberg W, Opelz G,. Switch from cyclosporine A to tacrolimus in renal transplant recipients: impact on Th1, Th2 and monokine responses. Hum Immunol 2000; 61: 884.
29. Weimer R, Schweighoffer T, Schimpf K, Opelz G,. Helper and suppressor T-cell function in HIV-infected hemophilia patients. Blood 1989; 74: 298.
30. LaRosa DF, Rahman AH, Turka LA,. The innate immune system in allograft rejection and tolerance. J Immunol 2007; 178: 7503.
31. Knoll GA, MacDonald I, Khan A, et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381.
32. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006; 82: 102.
33. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876.
34. Opelz G, Döhler B,. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. Transplantation 2009; 87: 795.
35. Niemczyk M, Zegarska J, Pawlowska M, Wyzgal J, Ciszek M, Paczek L,. Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor. Transpl Immunol 2009; 20: 139.
36. Rostaing L, Puyoo O, Tkaczuk J, et al. Differences in type 1 and type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporine A vs tacrolimus) in stable renal allograft recipients. Clin Transplant 1999; 13: 400.
37. Zamauskaite A, Cohen S, Sweny P, et al. FK506 and CsA differ in their effect on intracellular cytokine expression following kidney transplantation. Transplant Proc 2001; 33: 1046.
38. Merville P, Pouteil-Noble C, Wijdenes J, Potaux L, Touraine JL, Banchereau J,. Detection of single cells secreting IFN-gamma, IL-6, and IL-10 in irreversibly rejected human kidney allografts, and their modulation by IL-2 and IL-4. Transplantation 1993; 55: 639.
39. Moffatt SD, Cockman M, Metcalfe SM,. STAT 6 up-regulation by FK506 in the presence of interleukin-4. Transplantation 2000; 69): 1521.
40. Hackstein H, Klüter H, Fricke L, Hoyer J, Bein G,. The IL-4 receptor alpha-chain variant Q576R is strongly associated with decreased kidney allograft survival. Tissue Antigens 1999; 54: 471.
41. Mytilineos J, Laux G, Opelz G,. Relevance of IL10, TGFbeta1, TNFalpha, and IL4Ralpha gene polymorphisms in kidney transplantation: a collaborative transplant study report. Am J Transplant 2004; 4: 1684.
42. Langan LL, Park LP, Hughes TL, et al. Posttransplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007; 7: 847.